An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triple-negative breast cancer.
Medicine (Baltimore)
; 102(30): e34486, 2023 Jul 28.
Article
en En
| MEDLINE
| ID: mdl-37505137
ABSTRACT
BACKGROUND:
Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets the human trophoblast cell-surface antigen 2 to deliver SN-38 to cancer cells. In this study, we assessed the efficacy and safety of SG in patients with relapsed or refractory metastatic triple-negative breast cancer (RM-TNBC).METHODS:
For this integrated analysis, from inception to January 2, 2023, we searched PubMed, Web of Science, Embase, and Cochrane library databases for prospective studies that evaluated SC in RM-TNBC patients. Primary endpoints were survival outcomes and responses. Secondary endpoints were all grade and gradeâ ≥â 3 toxicities.RESULTS:
Six hundred potentially relevant records were screened. Our analysis included 3 trials (412 patients). Median overall survival was 12.9 months (95% confidence interval [CI], 11.5-14.4), progression-free survival was 5.7 months (5% CI, 5.1-6.3), and duration of objective response was 7.4 months (5% CI, 5.8-9.0). The objective response rate was 34%, and the disease control rate was 71%. Key gradeâ ≥â 3 toxicities (in over 10% of the patients) included neutropenia (46%), leukopenia (12%), febrile neutropenia (11%), diarrhea (11%), and anemia (10%). Four treatment-related deaths were reported.CONCLUSION:
SG was associated with effectiveness in patients with RM-TNBC. Myelosuppression and diarrhea were the primary treatment-related adverse events.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Inmunoconjugados
/
Neoplasias de la Mama Triple Negativas
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Medicine (Baltimore)
Año:
2023
Tipo del documento:
Article